Actively Recruiting
Newer Therapeutic Targets in Head and Neck Cancers
Led by Banaras Hindu University · Updated on 2024-08-13
200
Participants Needed
1
Research Sites
560 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); 2. cell-cycle control (e.g., CDKN2A and CCND1); 3. cellular differentiation (e.g., NOTCH1); and 4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways. Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known
CONDITIONS
Official Title
Newer Therapeutic Targets in Head and Neck Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically proven cases of primary head and neck cancers.
You will not qualify if you...
- Patients under 18 years of age
- Pregnant and lactating women
- Multiple cancers or patients with cancer of other sites.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Banaras Hindu University
Varanasi, Uttar Pradesh, India, 221005
Actively Recruiting
Research Team
M
Manoj Pandey, MS, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here